Jane Street
ACRS icon

Jane Street’s Aclaris Therapeutics ACRS Stock Holding History

Jane Street’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$346K Buy
+92,200
New +$311K ﹤0.01% 8903
2025
Q1 		– Sell
-18,900
Closed -$46.9K – 9299
2024
Q4 		$46.9K Buy
+18,900
New +$47K ﹤0.01% 8989
2023
Q4 		– Sell
-127,700
Closed -$875K – 9110
2023
Q3 		$875K Buy
+127,700
New +$1.09M ﹤0.01% 5391
2022
Q4 		– Sell
-10,300
Closed -$162K – 9023
2022
Q3 		$162K Sell
10,300
-100
-1% -$1.57K ﹤0.01% 8346
2022
Q2 		$145K Sell
10,400
-1,800
-15% -$25.2K ﹤0.01% 8429
2022
Q1 		$210K Sell
12,200
-4,400
-27% -$60K ﹤0.01% 8969
2021
Q4 		$241K Buy
16,600
+3,000
+22% +$45.5K ﹤0.01% 8536
2021
Q3 		$245K Sell
13,600
-7,500
-36% -$120K ﹤0.01% 8541
2021
Q2 		$371K Buy
21,100
+3,600
+21% +$81.8K ﹤0.01% 7795
2021
Q1 		$441K Buy
+17,500
New +$342K ﹤0.01% 7022

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Jane Street's ACRS Position: Q1 2026 in Review

Jane Street sold out of Aclaris Therapeutics (ACRS) in Q1 2026, closing a stake of 27,216 shares — an estimated $91.8K sold.

Jane Street first reported a position in ACRS in Q2 2019 and held it in 19 quarters. The position peaked at $1.57M in Q2 2023. 136 funds tracked by Wall St. Rank hold ACRS as of Q1 2026.

  • Jane Street reported no remaining Aclaris Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 27,216 Aclaris Therapeutics shares in Q1 2026, an estimated $91.8K.
  • Jane Street first reported a position in Aclaris Therapeutics in Q2 2019 and held it in 19 quarters.
  • Jane Street's Aclaris Therapeutics position peaked at $1.57M in Q2 2023.
  • 136 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.